Literature DB >> 15220757

Pleurodesis for malignant pleural effusions: current controversies and variations in practices.

Sophie D West1, Robert J O Davies, Y C Gary Lee.   

Abstract

PURPOSE OF REVIEW: Malignant pleural effusions are common, and pleurodesis remains the best method to control re-accumulation of the pleural fluid. There are few randomized controlled trials studying the optimal management of malignant pleural effusions. A recent international survey of pleurodesis practice has highlighted variations in how pleurodesis is performed worldwide. Future research should target these areas of variation to determine the best practice protocols. RECENT
FINDINGS: The selection of pleurodesing agents remains controversial. Talc is more effective, but is associated with more adverse effects. Talc pleurodesis is followed by systemic and pulmonary inflammation. This is probably related to systemic embolization of talc following its intrapleural administration, though there are other potential causes that may also play a role.
SUMMARY: The practice of pleurodesis varies considerably among individual pulmonologists and among different countries, in most technical aspects. This review serves to highlight some of these variations in practice, as well as reviewing the current literature on pleurodesis practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220757     DOI: 10.1097/01.mcp.0000129756.87090.55

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  9 in total

1.  Establishment of a malignant pleural effusion mouse model: pathogenesis pathways.

Authors:  Kalliopi Domvri; Paul Zarogoulidis; Fotis Theodoropoulos; Haidong Huang; Konstantinos Zarogoulidis
Journal:  Transl Lung Cancer Res       Date:  2012-09

Review 2.  Medical thoracoscopy in China-the present status and the future.

Authors:  Jing-Yuan Liu; Liang Xiong; Min Zhang; Shi-Yuan Shuai; Xiao-Shan Wei; Lin-Lin Ye; Qiong Zhou
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

3.  Rapid pleurodesis is an outpatient alternative in patients with malignant pleural effusions: a prospective randomized controlled trial.

Authors:  Serkan Özkul; Akif Turna; Ahmet Demirkaya; Burcu Aksoy; Kamil Kaynak
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

4.  Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.

Authors:  Ianko D Iankov; Cory Allen; Mark J Federspiel; Rae M Myers; Kah Whye Peng; James N Ingle; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2012-02-14       Impact factor: 11.454

5.  PleurX catheter for the management of refractory pleural effusions in congestive heart failure.

Authors:  James P Herlihy; Pranav Loyalka; Jayaraman Gnananandh; Igor D Gregoric; Carl G W Dahlberg; Biswajit Kar; Reynolds M Delgado
Journal:  Tex Heart Inst J       Date:  2009

6.  The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications.

Authors:  Foteini Economidou; George Margaritopoulos; Katerina M Antoniou; Nikolaos M Siafakas
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

7.  Observational analysis on inflammatory reaction to talc pleurodesis: Small and large animal model series review.

Authors:  Jacopo Vannucci; Guido Bellezza; Alberto Matricardi; Giulia Moretti; Antonello Bufalari; Lucio Cagini; Francesco Puma; Niccolò Daddi
Journal:  Exp Ther Med       Date:  2017-11-07       Impact factor: 2.447

8.  The need for translational research in respiratory medicine.

Authors:  Y C Gary Lee; Grant W Waterer
Journal:  Transl Respir Med       Date:  2013-04-19

9.  Ability of procalcitonin to discriminate infection from non-infective inflammation using two pleural disease settings.

Authors:  Fiona J McCann; Stephen J Chapman; Wai Cho Yu; Nick A Maskell; Robert J O Davies; Y C Gary Lee
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.